Biosimilars | Access & Reimbursement | US/EU5 | 2018
Payers play a significant role in defining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential reimbursement. Although biosimilars such as Pfizer’s Inflectra are available both in Europe and the United States, the level of their success can vary due to regional differences in the drivers and barriers to biosimilar uptake. As such, it is necessary for biosimilar developers and manufacturers of branded biologics to understand which factors influence payer decisions regarding biosimilars.
Questions answered:
- What are payers’ perspectives on the drivers of and barriers to biosimilar uptake?
- What factors influence which biosimilars are preferred on formularies in the United States?
- How do payers choose between multiple biosimilars of the same brand in the EU?
- What strategies do payers use to manage biosimilars?
- What expectations do payers have for biosimilar discounts?
- How would the availability of biosimilars influence the pricing of emerging agents?
- Will payer strategies for biosimilars differ between therapeutic specialties?
Key markets covered:
- France.
- Germany.
- Italy.
- Spain.
- United Kingdom.
- United States.
Key companies mentioned:
- Amgen.
- Boehringer Ingelheim.
- Celltrion.
- Eli Lilly.
- Hospira.
- Janssen.
- Johnson & Johnson.
- Merck & Co.
- Mundipharma.
- Mylan.
- Novartis.
- Pfizer.
- Roche.
- Samsung Bioepis.
- Sandoz.
- Sanofi.
- Teva.
Key drugs mentioned:
- Aranesp.
- Avastin.
- Basaglar.
- Benepali.
- Binocrit.
- Enbrel.
- Flixabi.
- Genotropin.
- Herceptin.
- Humira.
- Inflectra.
- Lantus.
- Neulasta.
- Neupogen.
- Nivestim.
- Omnitrope.
- Procrit/Epogen.
- Remicade.
- Remsima.
- Rituxan/MabThera.
- Truxima.
- Zarzio/Zarxio.
Related Market Assessment Reports
Report
Binge Eating Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Binge Eating Disorder (US)
Binge eating disorder (BED) is a prevalent condition in the United States; it affects millions of individuals across diverse demographics. BED is characterized by recurrent episodes of excessive…
Report
Opioid-Induced Constipation – Current Treatment – Treatment Algorithms: Claims Data Analysis – Opioid-Induced Constipation (US)
Opioid-induced constipation (OIC) is a condition in which bowel movements are infrequent or incomplete as a result of opioid medications. The treatment of OIC relies on various prescription…
Report
Chronic Obstructive Pulmonary Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Obstructive Pulmonary Disease (US)
Long-acting beta2 agonist (LABA) / long-acting muscarinic antagonist (LAMA) / inhaled corticosteroid (ICS) fixed-dose combinations (FDCs)—i.e., Trelegy and Breztri—have been gaining traction in…
Report
Diabetic Nephropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Diabetic Nephropathy (US)
Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The DN drug market comprises a wide variety of antidiabetic and antihypertensive drugs…
